Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Spinocerebellar Degenerations 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Carcinoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × epacadostat × Clear all
NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

University of Pittsburgh

Phase 1/2 Withdrawn
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡